Evidence map›Paper›PMID 20417554›Full record

ArticleBiomaterials2010

Biofunctionalization of electrospun PCL-based scaffolds with perlecan domain IV peptide to create a 3-D pharmacokinetic cancer model.

Olga Hartman, Chu Zhang, Elizabeth L Adams, Mary C Farach-Carson, Nicholas J Petrelli, Bruce D Chase, John F Rabolt

Abstract read
In one paragraph

Article in Biomaterials, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Olga HartmanDepartment of Materials Science and Engineering, University of Delaware, Newark, DE 19716, USA. ohartman@udel.edu
Chu Zhang
Elizabeth L Adams
Mary C Farach-Carson
Nicholas J Petrelli
Bruce D Chase
John F Rabolt
University of Delaware · USBiotechnology Institute · US

Funding

VOLUMETRIC BREAST DENSITY ESTIMATION USING BREAST SURFACE RECONSTRUCTEDP20RR016472 · NCRR · UNIVERSITY OF DELAWARE · PI STANHOPE, STEVEN J. · 2001 to 2011
$37.6M
Prostate Cancer Bone Metastasis: Biology and TargetingP01CA098912 · NCI · EMORY UNIVERSITY · PI ZAYZAFOON, MAJD · 2003 to 2019
$24.0M
High Speed Planar Array Infrared PA-IR SpectrographR33EB003288 · NIBIB · UNIVERSITY OF DELAWARE · PI RABOLT, JOHN FRANCIS · 2006 to 2008
$922k
NCI NIH HHS P01 CA098912NCRR NIH HHS 2 P20 RR016472-09NCRR NIH HHS P20 RR016472NIBIB NIH HHS 4R33 EB003288NIBIB NIH HHS R33 EB003288
6 · The paper itself

Abstract

Because prostate cancer cells metastasize to bone and exhibit osteoblastic features (osteomimicry), the interrelationships between bone-specific microenvironment and prostate cancer cells at sites of bone metastasis are critical to disease progression. In this work the bone marrow microenvironment in vitro was recreated both by tailoring scaffolds physical properties and by functionalizing electrospun polymer fibers with a bioactive peptide derived from domain IV of perlecan heparan sulfate proteoglycan. Electrospun poly (epsilon-caprolactone) (PCL) fibers and PCL/gelatin composite scaffolds were modified covalently with perlecan domain IV (PlnDIV) peptide. The expression of tight junction protein (E-cadherin) and focal adhesion kinase (FAK) phosphorylation on tyrosine 397 also were investigated. The described bioactive motif significantly enhanced adherence and infiltration of the metastatic prostate cancer cells on all modified electrospun substrates by day 5 post-seeding. Cells cultured on PlnDIV-modified matrices organized stress fibers and increased proliferation at statistically significant rates. Additional findings suggest that presence of PlnDIV peptide in the matrix reduced expression of tight junction protein and binding to PlnDIV peptide was accompanied by increased focal adhesion kinase (FAK) phosphorylation on tyrosine 397. We conclude that PlnDIV peptide supports key signaling events leading to proliferation, survival, and migration of C4-2B cancer cells; hence its incorporation into electrospun matrix is a key improvement to create a successful three-dimensional (3-D) pharmacokinetic cancer model.

Indexed as

Electrochemical TechniquesBiocompatible MaterialsBone MarrowCadherinsCell AdhesionCell Line, TumorCell ProliferationFocal Adhesion Protein-Tyrosine KinasesGelatinHeparan Sulfate ProteoglycansHumansMaleModels, BiologicalMolecular StructureNeoplasm MetastasisPeptidesBiocompatible MaterialsCadherinsFocal Adhesion Protein-Tyrosine KinasesGelatinHeparan Sulfate ProteoglycansPeptidesperlecanpolycaprolactonePolyesters

Identifiers

PMID20417554
PMCPMC2875366
OpenAlexW2130594839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.